Human Metabolome Technologies (6090)
Ryuji Kanno, President
Ryuji Kanno, President
Corporate Profile
Human Metabolome Technologies Inc.
Code No.
Mothers of Tokyo Stock Exchange
Service Industry
Ryuji Kanno
246-2 Mizukami, Kakuganji, Tsuruoka-city, Yamagata
End of March
Stock Information
Share Price Number of shares issued
(excluding treasury shares)
Total market cap ROE (Actual) Trading Unit
¥1,053 5,850,800 shares ¥6,160Mmillion -8.8% 100 shares
DPS (Est.) Dividend Yield (Est.) EPS (Est.) PER (Est.) BPS (Actual) PBR (Actual)
- - ¥-50.59 - ¥293.78 3.6 times
* Share price as of closing on the end of January 7. Number of shares outstanding, ROE and BPS are based on actual results of the previous term end.
Consolidated Earnings Trends
Fiscal Year Net Sales Operating
March 2013 (Actual) 496 -104 -93 -95 -24.52 -
March 2014 (Actual) 610 -12 5 1 0.38 -
March 2015 (Actual) 686 -100 -17 -34 -6.59 -
March 2016 (Actual) 780 -70 -71 -71 -13.41 -
March 2017 (Actual) 914 -43 -40 -61 -10.86 -
March 2018 (Actual) 938 -140 -149 -156 -26.92 -
March 2019 (Forecast) 1,100 -285 -285 -295 -50.59 -
* Forecasts are those of the Company. From the current fiscal year, the definition for net income has been changed to net income attributable to parent company shareholders (Abbreviated as parent net income).
This Bridge Report provides overview the First Half of Fiscal Year March 2019 earnings results, etc. of Human Metabolome Technologies Inc and an interview with President Kanno.
Key Points
Company Overview
Human Metabolome Technologies Inc. is a venture company originated from Keio University, which main focuses are: a) commissioned metabolome analysis service for research institutions and pharmaceutical companies and b) biomarker development. Its metabolome analysis technology is highly recognized throughout the world as a basic methodology to identify biomarkers. Its business model is to steadily generate profit through the commissioned metabolome analysis business while investing in and working on research and development of biomarkers which estimates future prospects. The company is pursuing continuous growth with a stable revenue base under this strategy. In 2001, Professor Tomoyoshi Soga of Keio University, Institute for Advanced Biosciences, developed a system to measure broad species of small-molecule metabolites (metabolome), which is called the CE-MS system. The new innovative system realized to capture a wide range of metabolites at once, while none of the conventional approaches do not, which means it used to be necessary to involve multiple experimental conditions, each of which has a small coverage. Metabolome analysis techniques had been used for various purposes such as fundamental biological research, development of pharmaceutical products, disease biomarkers, etc., and were expected to expand the demand in the future. Therefore, upon establishment of the CE-MS system, Human Metabolome Technologies Inc. was established in July 2003 to commercialize the method chiefly by Professor Soga, Professor Masaru Tomita, also from Keio University, and the office of Keio University. It was the first venture company originated from Keio University, with a financial support from Keio University's entrepreneurship fund. In 2008, Mr. Ryuji Kanno became the president of the Company. Before taking up this position, Mr. Kanno who was the Vice President & CEO of Agilent Technologies Japan, Ltd., a Japanese subsidiary of Agilent Technologies, a global company that develops, manufactures, sells, and support chemical analysis equipment and electric & electronic measurement equipment in the field of life science, which, had been for some time in business relationships with HMT and Keio University. President Kanno promoted research and development of the Company's core technologies and also began organizing and establishing more specific commercialization process and business models. At the same time, he began preparation for the Company to be listed on the stock market in order to accelerate its growth speed through enhancing the Company's visibility and raising funds for research and development. The Company got listed on the Mothers Section of the Tokyo Stock Exchange in December 2013, ten years after its establishment. 【Corporate Philosophy】 The Company defines the meaning of its existence as follows. "To contribute to people's health and joyful lives through research and development using the up-to-date metabolome analysis technologies for children in the future." The Company also sets the following 5 "Common Values 【Points to Understand the Company】 The Company's business overview is described later in this report together with the explanation of key words, "metabolomics" and "biomarker", however, many technical terms show up in the section, and that may prevent the readers from understanding. Here are three points briefly provided before jumping to the section to glancing at the Company's business scope. ① Significance of Social Presence Biomarkers are in vivo substances that are used as indicators to assess the current state of specific diseases. Blood sugar" for diabetes, "γ-GPT" for liver function disorder, and "uric acid" for gout are the representative examples of well-known and widely used biomarkers. The Company discovered a biomarker for "major depressive disorder", one of the current major social issues, and is developing diagnostic agents to quantify the condition of the disease. Because there is no prevailing method to objectively measure the status of depression, despite the increase in the number of patients with depression, some serious problems are emerging regarding the therapy of depression. For example, patients who would have been cured if they had properly treated are still suffering or in overprescription. If the diagnostic agents using the Company's biomarker become to be widely used, these issues are expected to be solved, and social loss will be subsequently reduced. This social significance cannot be overlooked to understand the Company. ② Excellent Technological Capacities The Company is highly recognized thanks to the "metabolome analysis technology" which is used to examine the complicated behavior of metabolites in human bodies to identify biomarkers. The biomarker for depression is just an example. In Oct. 2017, the biomarker for acute encephalopathy was patented in Japan. With the technology, the Company is expected to identify and develop various new biomarkers in the future. ③ Stable Business Model The Company's current core business is the "commissioned metabolome analysis business", supporting research and development activities of research institutions and pharmaceutical companies that occupy the greater part of its sales. Sales of FY March 2018 were 936 million and operating income was 445 million, showing steady income. On the other hand, the "biomarker business", which is expected to achieve significant growth in the mid- to long-term, is still operated in a small scale and experiencing losses. However, the Company has already established a balanced business model, in which the profit generated from the commissioned metabolome analysis business is invested into the biomarker business for its growth. This model is notable among many bio-venture companies that are suffering from gaining profit. ◎What is Depression? Depression is a type of mood disorder and is a brain dysfunctional state for various reasons such as accumulated physical and mental stress. Because the brain is not functioning properly, people in the depressed mood feel negative and low-esteem. This causes a vicious cycle in which people with depression feel more stress for matters that they could otherwise handle. The "major depressive disorder" refers to the state in which depression mood continues even after the sources of stress are removed. In this regard, it is distinguished from adjustment disorders or some anxiety disorders and is considered a brain dysfunction, instead of a mere response to stress. (Note: "Major" of the major depressive disorder means "primary" and does not mean "serious" depression.) ◎Number of depression patients in World and Japan In 2012, the World Health Organization (WHO) announced that at least 350 million people were with depression which is a mental disorder. Almost 1 million lives are lost due to suicide every year, and over half of them are assumed to be due to depression. According to the "Patient Survey" conducted by the Ministry of Health, Labor, and Welfare (MHLW) every three years targeting health facilities across the country, the total number of patients with mood disorders including depression increased from 430,000 in 1996 to 950,000 in 2011 (2.2x). The "Patient Survey" shows statistical data of the number of patients who visit health facilities. It is known that the consultation rate of patients with depression is low. Thus, according to the MHLW, it is suspected that the actual number of depression patients might be larger. It is said that majority of depression patients are women and young people, however, in Japan, it is also frequently found among middle-aged people, and the social and economic impact of depression is significant. Needless to say that depression distresses both patients and their families, and its social aspects cannot be passed over either; it leads reduction on the productivity of organizations and even suicide. In Japan, economic losses due to depression and suicide are estimated to be about 3 trillion yen. If there were no such losses, GDP would increase about 2 trillion yen (an estimate by the Ministry of Health, Labour and Welfare, 2010). Economic losses around the world are estimated to be about 62 trillion yen in 2002 (Screening for Depression in Adults: A Summary of the Evidence. Ann Intern Med. 2002.). The current economic losses are estimated to be over 100 trillion yen. ◎Treatment of Depression If someone is diagnosed as having depression, the common treatment is prescription of "antidepressant drugs." The antidepressant drugs can be categorized into several groups such as selective serotonin reuptake inhibitor (SSRI), serotonin-noradrenaline reuptake inhibitor (SNRI), and tricyclic antidepressant. In addition, anti-anxiety drugs or sleep inducing drugs can be used, depending on the symptom. The important thing under drug therapy is that the patients comply with the prescribed amount and frequency after they are informed about the effects and side effects. However, patients with depression often reduce the amount or frequency without doctors' permission as they do not feel the symptom to be very serious, they worry side effects, etc. In these cases, the patients do not show improvement as doctors expect, and the doctors prescribe more drugs or change the types of drugs. That would often result in the delay of recovery or excessive administration of drugs, for lack of trust between doctors and patients. Therefore, it is essential to have objective assessment standards quantifying the state of depression or proving the depression has been cured. The biomarker and diagnostic agents of the depression that the Company is currently working on are extremely important for prompt and appropriate treatment of the disease. 【Metabolomics and Biomarker】 In order to understand the outline of the Company's business activities, it is necessary to have a certain understanding of two key words, "metabolomics" and "biomarker". <What is metabolomics?> Living organisms including human beings consist of some parts with various functions such as muscles, internal organs, and bones. "Metabolites" such as amino acids, fatty acids, and nucleic acids are common and major components of these organs. Metabolites play crucial roles for entire life activities. Metabolites are provided by food and are consumed in the process of daily actions such as exercise. They move in a body and cells in accordance with their functions and are converted into new substances through various chemical reactions, which are called "metabolism". Adjusting body temperature, breathing, moving heart, digesting and absorbing food, transforming old cells into new ones are all operated by metabolism. The "substance conversion" to a new substance is based on a certain flow called metabolic pathway. One of well-known approaches to understand the mechanisms of a human body is "genomics", analyzing genes. Now, automated sequencing and computer analysis of genetic information (DNA base sequences) is available, and nearly all the information in the human genome has already been deciphered. However, much about the relationship between the roles of genes and diseases remains unknown. Recently, more researchers lean towards investigating metabolic profiles, in addition to genetic information coming out of genome analysis, in order to understand the relationships between a human body and diseases. Consequently, research and use of "metabolomics (metabolome analysis)" targeting all metabolites is becoming increasingly popular. The metabolome analysis is mainly used in the following fields: <What are biomarkers?> A human body puts various vital functions under high-sophisticated manipulation to minimize internal and external influences, and subsequently keeps the body condition stable. That mechanism is called "homeostasis". For example, body temperature and heartbeat may change temporarily, but return to regular ranges. Diseases lead abnormal homeostasis and metabolic status, which are different from healthy conditions. A metabolite, which concentration keenly reflects the status of a specific disease, is called a biomarker. By measuring a biomarker, the current status of a specific disease can be objectively assessed. Blood sugar as a pancreas function indicator, γ-GTP as a liver function indicator, biomarker PSA for prostatic cancer and biomarker CA19-9 for pancreatic cancer are examples of well-known biomarkers. Biomarkers have been studied for a long time in order to monitor the status of diseases. These days, with new methods to analyze multiple substances with higher sensitivity all at once, study results of various new biomarkers have been publishing one after another. Among the biomarkers that are explored through metabolomics technologies are the followings: 【Business Contents and Business Model】 The main businesses pillars of the Company are the "commissioned metabolome analysis business" and "biomarker business". It is trying to expand the metabolome study related market by disseminating the excellence of its CE-MS system, the Company's core technology, to research institutions and pharmaceutical companies, and securing income base by expanding the metabolome analysis business in Japan and overseas. Previously, the company allocated the profit from the "metabolome analysis business," which is the current mainstay business, to the investment in the R&D of the promising "biomarker business," and applied the intellectual property obtained through the R&D to the development of medicines and disease diagnosis, with the goal of growing in the mid to long terms. From the term ending Mar. 2017, the company will accelerate the investment in the biomarker business by procuring funds from the outside in order to flourish in the future. Earnings structure and customers of each business are as follows. ① Commissioned Metabolome Analysis Business "Sales were 936 million yen and operating income was 445 million yen for FY March 2018." The Company receives orders from various customers, e.g., private companies such as pharmaceutical companies and food companies as well as universities and public research institutes. The scheme of the service is as follows. A customer sends samples to the Company, and then metabolites are extracted from the samples. The extracted metabolites are measured by the CE-MS system, and the acquired data is analyzed. After all, the report is delivered to the customer. The data obtained from the service are used for various purposes; basic biological study, assessment of drug effectiveness and toxicity assessment by pharmaceutical companies, universities, and research institutions, analysis of fermentation process and functional evaluation of functional foods by food companies. The data is contributing to the progress of research and development activities of customers. In recent years, not only healthcare, food, but also interest towards health-related companies is emerging rapidly. The Company has not only accumulated a wealth of achievements with a total of 4,750 tests since the foundation up to the fiscal year 2017, but also receives a high reputation from customers for their quality. ◎Deployment in the Overseas Market In order to distribute the commissioned metabolome analysis service in Asia, the Company concluded an exclusive sales authority agreement with Young In Frontier Co., Ltd. in South Korea in June 2011. Moreover, the Company hired a sales representative in charge of Asia-Pacific area to develop Asian market including Singapore and Hong Kong, outside of South Korea. Furthermore, in order to expand its business in the North American market, it also established its sales subsidiary, Human Metabolome Technologies America, Inc., in October 2012 at Cambridge, Massachusetts, USA, home to many medical research institutions. In order to further accelerate overseas development, in May 2017, the company established a subsidiary (sub-subsidiary) "Human Metabolome Technologies Europe B.V." in Europe (Netherlands) through HMT-A. ◎"C-SCOPE" -a service package of the commissioned metabolome analysis service for cancer study In August 2012, the Company launched "C-SCOPE", a service package of the commissioned metabolome analysis service well organized for cancer study. C-SCOPE was developed to respond to the needs; they would like to measure concentrations of specific metabolites changing inside cancer cells with higher sensitivity and higher accuracy. Its technologies are based on unique and efficient metabolites extraction method from cancer cells and highly sensitive analytical system. Cancer is the number one cause of death in Japan since 1981 and occupies about 30% of the recent total causes of death. According to the MHLW, the costs for cancer research are increasing year by year; in 2012, ¥35.7 billion were spent. It is an urgent task for many pharmaceutical companies to develop effective new anticancer drugs. The "Warburg effect" is the phenomenon that most cancer cells have glycolytic rates of several to dozens of times to that of normal cells. Although this effect was proposed as far back as over 80 years ago, the research on the effect made little progress since there was no method to comprehensively measure metabolites back then. Thanks to the dramatic advancement in metabolomics technologies in recent years, development of anticancer drugs which act as metabolic inhibitors are underway. The Company's metabolome analysis technology based on the CE-MS system is considered as one of the effective analysis systems applicable at each stage of cancer research; from the basic study of cancer biology to clinical application in the process of anticancer drugs development. ② Biomarker Business "Sales was 2 million JPY and operating loss was 185 million JPY for FY March 2018" The Company considers the business related to biomarkers, which play an important role in occasions such as early diagnosis or monitoring treatment effects, as a driver for future growth, and is proceeding with biomarker discovery and development of clinical test drugs through collaborative research and development with universities, pharmaceutical companies, and diagnostic drugs companies. The Company develops new diagnostic methods by using biomarkers, which were acquired through its own R&D, or biomarkers introduced from outside. Additionally, through the process of product development and clinical development, the Company produces and sells in vivo diagnostic drugs and diagnostic equipment. The sales in this business are composed of cooperation money for R&D from pharmaceutical companies in cooperative research, milestone revenues, and loyalty gained from the sales of the drugs when they are commercialized. ◎Intellectual Property Policy The personnel in charge of intellectual property and contracts works on patent application and requests for examination of all projects and are in close collaboration with the patent attorneys of the Company and its collaborative research institution. They are also responsible for negotiation concerning collaboration research agreements and development of agreement documents. The Company attempts to maximize its rights when obtaining a patent of newly discovered biomarkers. Since the scope of the rights differs depending on the marker, the Company generates patent application documents in a way that would cover a wide scope of the rights such as chemical structure of the biomarker, usage for diagnostics and drug development, detection method and measurement equipment. Furthermore, the Company makes it a principle to file international patent applications in accordance with the Patent Cooperation Treaty, in anticipation for the future license agreement and market based on the information of clinical test drugs, test equipment companies and pharmaceutical companies of various countries. As of June 2017, the "basic patent" on the method of biomarkers of depression diagnosis etc. has been registered in Japan, the US and China (Europe has been filed). The patent on the method of measuring ethanolamine phosphate (PEA) has been registered at all four stations in Japan, the US, China and Europe. ◎Example of Biomarker Business: Depression Biomarker The Company especially focuses its research and development on a) the central nervous system disorder such as depression (e.g. mood disorder and mental disorder) for which there are few objective diagnosis methods b) diseases that have become social problems such as metabolic syndrome, including hepatitis and diabetes, and their related diseases. Its current focus is the biomarker for depression. Diagnosis of the major depressive disorder is conducted using the diagnostic standards provided by the American Psychiatric Association or the standards of the World Health Organization (WHO). However, both of them largely reflect the subjective view of the doctor or patient, and unlike other diseases, no diagnostic method has been established on the basis of objective indicators. The Company conducted collaborative research with the National Center of Neurology and Psychiatry, and discovered a blood biomarker of the major depressive disorder. Blood samples were collected from approximately 30 patients and 30 healthy people, and the blood components were compared through metabolome analysis using the CE-MS system. As a result, the patients with major depressive disorder showed lower concentration of (PEA) in their serum. Through further analysis, it was found that a) PEA is a specific biomarker for major depressive disorder, and b) PEA level will return to the healthy standard range when MDD is treated. *Companion diagnostics: Refers to clinical tests to predict effects and side effects of pharmaceutical products before administration. By checking the responses of individual patients towards a drug before treatment, more effective drug administration can be provided. As described earlier, the Company explores, studies and analyzes the mechanisms of PEA and depression. Meanwhile, they developed an instrumental analysis measurement method, which improved the Company's measurement accuracy and enabled them to study treatment effects and condition of diseases. Subsequently, the Company developed a technology to measure extremely low-concentrated PEA in the blood, which was not possible to detect with the conventional enzyme method. Based on this technology, the Company developed the "PEA test kit using the enzyme method" (β-version) in 2016. It is of extreme significance that the Company succeeded in the development of a "depression biomarker test kit" (β-version). "Realization of an inspection method that can be processed cheaply and massively" and "Establishment of a technical foundation that can supply reagent kits worldwide" will make it possible to supply PEA tests to 350 million people with depression worldwide. As a result, the company's significance of social existence has become even bigger. In addition, it has become possible to shift to a new business development phase that considers concrete markets, product specifications, distribution channel construction, business size, etc. ◎Identification of Disease Biomarkers The Company uses the following three connections and systems for identifying biomarkers in order to expand biomarker development pipelines. <Connection with the Customers for Commissioned Analysis or Collaborative Development> The Company accepts requests from universities and companies for the tests for finding biomarkers. The Company also receives proposals for collaborative development before or after the tests. Currently, a collaborative development project for diabetic nephropathy biomarkers is ongoing. <Direct Proposal to Researchers and Physicians> The Company's researchers directly propose research plans for the development of disease biomarkers to researchers or physicians, and establish collaborative study agreement with the institution based on approvals from the collaborative researchers or physicians. The target diseases are chosen according to the number of patients, compatibility to the analysis technologies of the Company, degree of social contribution, and necessity of biomarkers. In addition to major depressive disorder, the Company is working on the development of biomarkers for non-alcoholic steatohepatitis and fibromyalgia. <HMT Research Grant for Young Leaders in Metabolomics> The Company offers a grant (HMT Research Grant for Young Leaders in Metabolomics) to graduate students to disseminate the usefulness of metabolomics in the society and nurture young researchers. From the research themes submitted from graduate students across the world, the Company chooses excellent proposals, and supports their research by awarding metabolome analysis service without a fee. Fourteen students have been awarded in the last 4 years. Some of these study results actually led to the identification of biomarkers and evolved to collaborative study with the Company, for example, infectious disease-related encephalopathy biomarker. In March 2017, the company announced that it acquired a technology patent concerning the next generation biomarker. Currently it is difficult to detect with conventional CE - MS metabolome analysis technology because γ - glutamyl dipeptide, which is a biomarker for liver diseases currently under development at the company, exists in trace amounts in vivo, but using this patented technique , it is now possible to comprehensively detect γ - glutamyl dipeptides. According to this patented technology, it is possible to realize highly sensitive detection of 50 times or more depending on the substance, therefore it is possible to dramatically improve CE-MS metabolome analysis technology of the company, and the possibility of discovering new innovative biomarkers is also expected to increase. Furthermore, in Oct. 2017, the "method for detecting encephalopathy" was patented in Japan, as the company and Nagoya University jointly applied for the patent. Encephalopathy occurs due to the infection with viruses, bacteria, or the like, and induces the impairment of consciousness, spasm, abnormal behavior, hallucination, etc. Especially, acute encephalopathy, such as influenza-associated encephalopathy and HHV-6 encephalopathy, occurs to children, and in many cases, it progresses rapidly and becomes severe. Accordingly, it is necessary to diagnoze them early and offer appropriate treatment immediately. In collaborative research with Nagoya University, the company discovered a candidate biomarker for detecting acute encephalopathy, and made it patented.
The First Half of Fiscal Year March 2019 Earnings Results
Loss continues due to increasing investment for growth. Sales were 276 million yen, down 10.1% year on year. The large-scale projects, which were recorded in the same period last year in the metabolome analysis business, were not posted this term. Operating loss stood at 293 million yen. Profit went down in the metabolome analysis business due to a sales decrease and growing investment (increases in the numbers of personnel and facilities). In the biomarker business, the company has been making investment on a continuous basis with the aim of commercializing depression biomarkers. Sales shrank 10.1% year on year to 276 million yen. While the company is expanding primarily into the food product industry, this term, it did not receive orders for large-scale projects, which were recorded in the same period last year. Operating income was 5 million yen, down 91.1% year on year. The company propelled forward facility and organizational enhancement for launching new analysis plans. The amount of orders received and order backlogs were both sluggish, dropping 32.9% and 22.1%, respectively, year on year. Current assets decreased by 325 million yen from the end of the previous term due to a drop in trade receivables. Noncurrent assets increased 63 million yen from the end of the previous term owing to a rise in property, plant and equipment, resulting in total assets of 1,658 million yen which went down 262 million yen from the end of the previous term. Total liabilities remained almost unchanged. Net assets shrank 266 million yen from the end of the previous term to 1,485 million yen due to the widening deficit of retained earnings. As a result, equity ratio declined 2.8 points from 89.2% at the end of the previous term to 86.4%. The deficit of operating CF decreased owing to a decrease in trade receivables. Investing CF turned positive thanks to proceeds from redemption of securities and other sources. Free CF improved. The cash position degraded. (4) Topics ① Released new services in the metabolome analysis business The company released 3 new services in the business. * "Mediator-Scan" This service was released in April 2018, and it analyzes about 400 spicies of fat-soluble metabolites, including the representative agent group of the so-called lipid mediator. As the "lipid mediator" relates to extremely diverse physiological functions, "Mediator-Scan" is the plan best suited for elucidating medical conditions and exploring biomarkers for a myriad of diseases, ranging from asthma, urticaria, rheumatism, inflammatory bowel disease, atopy and food allergy that are related to immunity and inflammation. In addition to them, it is also effective in lifestyle-related diseases, such as diabetes and arteriosclerosis, and cancer and dementia. The analytical comprehensiveness of "Mediator-Scan" will be further enhanced in combination with other existing analysis services that HMT offers in commission. * "Q-OPTION" This service was made available in July 2018. It is an optional service that quantifies concentrations of selected 403compounds with one-point calibration which are detected most frequently, of about 900 substances subject to analysis by the CE-MS method that is the mission-critical technology of the company. This service is the extended version of "Target Concentration Calculator" that provides quantitative values for the conventional 110 substances. "Q-OPTION" is the best optional plan not only for long-term data collection, such as database establishment and cohort studies, but also for stoichiometric numerical analysis. * "ωScan" This service was launched in October 2018. CE-FTMS (Orbitrap mass spectrometer, or OrbitrapMS), which is the company's original patented platform, is characterized by high resolution and stable mass accuracy. In general, it can be used in a wide range of application fields, including drug metabolism, impurity analysis, natural products, metabolomics, and proteomics. The sensibility is several times or several tens of times better than the conventional CE-TOFMS method, almost doubling the number of substances to be detected, compared to conventional products of the company. Users will be able to collectively detect metabolic substances whose concentration in their living bodies are extremely low, and there is a high possibility of discovering completely new biomarkers, which could not be found with the existing technologies or services of other companies. The company forecasts that the service will make contributions not only in Japan but also to market expansion in the United States and Europe, and acceleration of business expansion into the Chinese market. ② Embarked on development of the Chinese market As described in the previous reports, in China, the number of papers published by research institutes has already been about four times larger than in Japan, significantly exceeding the United Kingdom and South Korea, and hotly pursuing the United States, the leading country. In Asia, China has made a great research power that has occupied the first place in the fields of chemicals, physics, and global environment, and the second place in the life science field. Giving an eye to such marketability, the company has considered breaking new ground in China, and it decided to fully develop the Chinese market, starting in the term ending March 2019, as the company has become sufficiently rich in human resources. The company is propelling forward preparation swiftly by securing multiple key opinion leaders (KOLs) who are essential for market development, and recruiting Chinese staff dedicated to sales activities. Furthermore, it is scheduled to complete securing of human resources and development of facilities for establishing a preprocessing system within this term. As shown in the picture below, the company expects that the Chinese market will grow to the scale that exceeds the markets in Japan or various European nations in the coming several years, and thus, it will expand the metabolome analysis business into overseas markets at an accelerated rate together with its subsidiaries in the United States and Europe. ③ Change in the end of the fiscal period The company has decided to change the last month of the fiscal period from the end of March, which is currently adopted, to the end of June. The reasons behind the change are (1) to mitigate the impact of seasonal fluctuations in sales and other factors on business performance and (2) to effectively formulate business plans because the metabolome analysis business of its mainstay is the peak season between January and April. As the term ending June 2019 falls under the transition phase to a new fiscal period, the term will be for 15 months, starting on April 1, 2018 and ending on June 30, 2019.
Fiscal Year March 2019 Earnings Estimates
The earnings estimates have remained unchanged. The metabolome analysis business will continue to be strong, and sales will increase. Due to upfront investment for both businesses, the amount of loss will increase. Sales are forecasted to be 1.1 billion yen, up 17.2% year on year. The metabolome analysis business continued to be healthy. The loss range will be larger due to active investment in both businesses. (2) Efforts of this term The company lists the following 4 management policies. ① Sustainable growth of sales and attainment of a budget. The company will create a foundation for medium-term leap by exploiting new fields and areas by new products and developing new businesses. ② Equipment investment in the analysis business The company will make a capital investment corresponding to new product development and double the analysis/ production capacity in the medium term. ③ To ensure commercialization of depression biomarker The company will develop an exit strategy to accelerate clinical research and obtain pharmaceutical approval of the PEA reagent kit. ④ To continue securing stable shareholders and maintaining them via dialogues. The company will continue focusing on IR activities for institutional investors and individual investors. (External environment) Metabolomics has advanced from traditional academic technology for universities and laboratories to industrial technology. Under these circumstances, health-conscious markets with keywords such as new health food products including functional foods, sports, food, sleep, and stress are interested in the usefulness of metabolomics to grasp human health status, and new markets are being created. In addition, the drug development field is starting to pay attention to the benefit of using metabolomics for research on intestinal bacteria, early detection, diagnosis and development of therapy for psychoneurotic diseases such as dementia and Alzheimer's disease, and practical application of medical technology including drugs for refractory diseases. (Key measures) In the following wind, the company is planning to undertake the measures below and steadily expand the businesses. (Points of each measure) Regarding the measure "(1) sales increase by developing new products in the growing fields," as mentioned earlier, the company has released 3 new plans in a bid to take in demand more extensively. In the measure "(2) further focus on overseas expansion," the company will embark on development of the Chinese market that is expected to thrive rapidly. Considering that the needs for its metabolome analysis technology is strong, the company will accelerate expansion of the metabolome analysis business into overseas markets together with its subsidiaries in the United States and Europe. The company deems its "original platform CE-OrbitrapMS" to be the key to breaking fresh ground. As for "(3) New business development", the health-conscious market is focusing on the utility of metabolomics to understand human health status, and new markets are being created. The company expects that the needs for the healthcare industry will be enhanced to clarify and examine mechanisms of dietary effects and exercise effects, and to accurately grasp and judge comfortable sleeping states and stress levels. Based on the dominant overwhelming achievement in the domestic market of 4,750 cumulative total number of tests up to the year 2017, the company is working on "health marker to detect health", "marker to discover state of mind" , "Markers that contribute to the prevention of disease" and so on.
Progress of the Biomarker Business
As a result of the development of "PEA test kit using the enzyme method," the company will be able to supply PEA tests to 350 million patients with depression all over the world. It is now steadily developing a foothold for commercialization. (1) Product development As for the enzyme method reagent kit for PEA test (for research), which is under development, through a collaborative research with Toyobo Co., Ltd. (3101, the first section of TSE), which is the second largest share of industrial enzymes in the world, the company established mass production technology of enzymes used for measuring depression-related biomarkers and established a system capable of improved and stable supply. It is working on establishing manufacturing and sales systems of reagents and customer correspondence system and preparing for large-scale sales. At the same time, it began fee-based shipment in the previous fiscal year. During this fiscal year, it will start offering fee-based shipment to research institutes and collecting customers' opinions. In addition, the company is striving to improve the reagent kit for large biochemical test equipment. Meanwhile, the company planned to develop two types of methods for measuring PEA, which are the "measurement at large-sized hospitals and clinical test centers using a measurement reagent kit and versatile automatic biochemical test instrument" and the "measurement at general internal departments and mental health clinics using measurement a reagent cartridge and small-sized POCT measurement instrument capable of swift examinations"; however, for the latter method, it was required to develop a POCT measurement instrument and a measurement reagent cartridge that are essential for allowing as many joint research institutes as possible to conduct clinical measurements. Therefore, judging that it was more appropriate to prioritize a pharmaceutical application with not a POCT measurement instrument but a PEA test and research reagent kit for high-speed liquid chromatography, and proactively invest in making a reagent kit using the enzyme method available for large-sized equipment and implementating clinical study for obtaining pharmaceutical approvals in a swift and reliable manner, the company completed the development of the PEA test and research reagent kit for high-speed liquid chromatography. *Ion-chromatography (IC-FLD) has been renamed "high-speed liquid chromatography (HPLC)" that is the name as medical equipment. (2) Clinical development The progress of clinical research and academic research indispensable for obtaining licenses as in-vitro diagnostic drugs is as follows. (Clinical development) Concerning the performance test of plasma PEA by a case-control study, the company-led feasibility test is in progress. The company is in the process of scheduling collaborative research with domestic university hospitals and US university hospitals on verification of relevant diseases, genetic background and racial differences by domestic and foreign cohorts. As for preparation for domestic clinical trials, a partial contract was completed to start working collaboratively with domestic university hospitals. (Academic research) For elucidation of the decreasing plasma PEA mechanism by depression model animals, joint research with domestic universities was conducted, and a decrease of plasma PEA in the model animals was confirmed. Joint research with domestic universities is underway to verify the effect of antidepressant administration on plasma PEA concentration among model animals. The company is conducting joint research with US National Institute of Health on the elucidation of PEA generation mechanism in brain using biochemical methods. In January 2018, an article on the major depressive disorder biomarker was published in the journal of the Japan Society of Psychiatry and Neurology. According to this article, metabolome analysis comparing the blood components between major depressive disorder patients and healthy volunteers revealed a metabolome profile characterizing the major depressive disorder patients with PEA as a biomarker. (Summary) The metabolome analysis of the patients with major depressive disorder and healthy subjects by the CE-MS method, which is the company's core technology, revealed that plasma PEA among the patients was significantly lower than that of healthy subjects. As a result of the measurement of plasma PEA of the patients with and without major depressive disorder by the ion chromatography-fluorescence detection (IC-FLD) method, plasma PEA showed high discrimination performance as a biomarker of the major depressive disorder patients. Comparison of the PEA between the patients with and without major depressive disorder was carried out as a verification test. The results showed that the plasma PEA concentration was a promising biomarker candidate for major depressive disorder. (3) Pharmaceutical affairs In addition to obtaining the permission for the manufacture and sale of pharmaceutical products for in-vitro diagnosis in the fiscal year before last, the company obtained the permission for "wholesale distribution of pharmaceutical products" in the previous fiscal year. As the company managed to advance the development of an important foundation for pharmaceutical business for the future commercialization, it will begin prior consultation for pharmaceutical applications with Pharmaceuticals and Medical Devices Agency during this fiscal year and will begin discussing specific exit strategies. (4) Business development As mentioned above, the company started offering fee-based measurement reagent kits (for research) in the previous fiscal year. The basic patent of the PEA enzymatic method is not yet registered in Europe, but it is expected to be registered soon. Furthermore, the company is examining the global PEA market and looking for partners.
Interview with President Kanno
We asked President Kanno about the current situation and prospects of both businesses and asked him to give messages to the shareholders and investors. Q: "What were the conditions in the metabolome analysis business in the first half of this term?" A: "It is really regrettable that profit declined, but the factors behind the drop include the timing of budget implementation mainly by academia. The market itself is healthy, which means that our company has never reduced our market share. The numbers of customers and inquiries are increasing, and the fact remains that the social utility value of metabolome analysis has become evident." It is really regrettable that profit declined because we did not receive orders for large projects which were placed in the previous term, but the factors behind the drop include the timing of budget implementation mainly by academia. The market itself is healthy, which means that our company has never reduced our market share. The number of customers and inquiries are increasing, and more and more private companies, especially food product companies that have been deeply interested in "quality control" and "verification of value" are now using our services; that is, the fact remains that the social utility value of metabolome analysis has become obvious. We will endeavor to raise the number of customers, prospect for customers who enter into annual contracts with our company, and develop customers in an attempt to diminish fluctuations in sales as much as possible. Our company has released new services one after another as powerful tools for taking in such demand on a steady basis. "Mediator-Scan" is capable of measuring the lipids that could not be measured in the past, and further increasing the analytical comprehensiveness in combination with other existing analysis services that our company offers in commission. "Q-OPTION" is a service that our company has developed by further extending the characteristics of our metabolome analysis technology with which we provide quantitative values. No other company offers a service of this kind. "ωScan," which uses our company's original platform CE-OrbitrapMS, is capable of detecting the substances that could not be found with the conventional methods, thanks to its high sensibility. We believe that this technological edge brings an advantage that the number of samples required will be smaller, and raise the possibility of discovering completely new biomarkers that could not be spotted in the past. As the only company that possesses this technology in the world, our company will strive to develop overseas markets by taking advantage of the overwhelming differences in performance. Q: "Your company is fully embarking on development of the Chinese market. Please tell us about the progress." A: "There is almost no doubt that the Chinese market will thrive considerably in the future. We have to hold discussion over a multitude of matters after examining and analyzing the conditions in the Chinese market, including the appropriate price and service level, and whether or not we should build our own facilities for analysis; however, Mr. Yuji Suzuki, who our company invited as an operating officer in July this year, is taking the lead in moving ahead with establishment of a system for sales and marketing activities." There is almost no doubt that the Chinese market will thrive considerably in the future. It is extremely vital for us to start driving a wedge firmly now. There are a multitude of matters to discuss after examining and analyzing the market conditions, including the appropriate price and service level, and the appropriate location to build facilities for analysis; however, to begin with, we are moving ahead with establishment of a system for sales and marketing activities. In an attempt to entice customers in the Chinese market, Mr. Yuji Suzuki (who was in charge of corporate strategies and global business expansion at Macromill, Inc. after working for the Ministry of Foreign Affairs of Japan, and the Japanese branch office of one of the leading consulting companies, McKinsey & Company, Inc.), who we invited as an operating office in July this year, has been powerfully taking the lead and fulfilling a substantial role. We would like to consider whether or not it is necessary to set up bases by the end of this term (the end of June 2019) and begin developing markets in a more full-fledged manner. Q: "How about the biomarker business?" A: "We cannot talk with confidence about some items, as the time has come to take into account pharmaceutical regulatory approvals and coverage by insurance; however, our company has made steady progress. In clinical studies, we have completed a feasibility test led by our company. We propelled forward product development, considering that it was appropriate to prioritize a pharmaceutical application with the test kit for high-speed liquid chromatography, and we have finished the development and completed the method. We will enter the stage where we will have to determine how to proceed with regulatory affairs." Regarding development, manufacturing, and sale of the PEA test kit, we cannot talk with confidence about some items, as the time has come to take into account a pharmaceutical approval and coverage by insurance; however, our company has made steady progress. In clinical studies, we have completed a feasibility test led by our company. In addition, we are in the final phase of arranging schedules for collaborative research with university hospitals in Japan and the United States concerning verification of related medical conditions, genetic backgrounds, and racial differences by Japanese and overseas cohorts, in order to eye the possibility of development and business expansion abroad from the perspective of the commercialization speed in parallel with the development and business expansion in Japan. As for product development, judging that it was appropriate to prioritize a pharmaceutical application of the test kit for high-speed liquid chromatography by targeting clinical examination centers and clinical examination offices in large-scale hospitals, and improve the enzymatic reagent kit for big biochemical examination instruments, our company has finished the development of the former kit and completed the method. Q: "In conclusion, please give messages to the shareholders and investors." A: "Our company has received invitations to enter into business alliances from a variety of companies recently, which would be because interest in the utility of metabolomics is growing rapidly amid the expansion of health-conscious markets. Our company will strive to realize monetization as soon as possible by utilizing these tailwinds and making the most of our company's technological competitiveness, and thus, we would like the shareholders and investors to support us on a continuous basis." While steadily taking in demand in the metabolome analysis business in Japan, our company will embark on development of global markets with our unique technology. Furthermore, Mr. Hashizume, one of the operating officers at our company, now serves as the president of a subsidiary HMT Biomedical, Inc. and is forging ahead with business development through novel approaches, such as searches for new biomarkers, that are out of the scope of commissioned analysis projects. Therefore, I would like all of the shareholders and investors to expect a lot from our company. Our company has reached a crucial phase where we aim to obtain pharmaceutical approvals in the biomarker business. It has taken us a while because weight should be attached to not only swiftness but also reliability. We kindly ask the shareholders and investors to be patient and follow the progress. Our company has received invitations from a variety of companies to enter into business alliances, which would be because interest in the utility of metabolomics is growing rapidly amid the expansion of health-conscious markets. We will strive to realize monetization as soon as possible by utilizing these tailwinds and making the most of our company's technological competitiveness, and thus, we would like the shareholders and investors to support us on a continuous basis.
Both sales and profit shrank in the metabolome analysis business that had been steadily expanding the top line; however, there is no need to concern as the competitive edge of the company in the metabolome analysis business will not change and interest in the utility of metabolomics continues to grow. Meanwhile, taking into consideration that the company has reached the critical stage of pharmaceutical approvals in the biomarker business, and its intent to focus more on reliability, we would like to keep paying attention to its future progress toward clearing up the challenges and achieving targets in the areas of product development, clinical development, regulatory affairs, and business development.
<Reference: regarding corporate governance>
◎ Corporate governance reports Updated on November 28, 2018 <Reasons for Non-Compliance with the Principles of the Corporate Governance Code (Excerpts)> It is mentioned that "Our company follows all of the basic principles of the Corporate Governance Code."
This report is intended solely for information purposes, and is not intended as a solicitation for investment. The information and opinions contained within this report are made by our company based on data made publicly available, and the information within this report comes from sources that we judge to be reliable. However, we cannot wholly guarantee the accuracy or completeness of the data. This report is not a guarantee of the accuracy, completeness or validity of said information and opinions, nor do we bear any responsibility for the same. All rights pertaining to this report belong to Investment Bridge Co., Ltd., which may change the contents thereof at any time without prior notice. All investment decisions are the responsibility of the individual and should be made only after proper consideration.
Copyright(C) 2018 Investment Bridge Co., Ltd. All Rights Reserved.